Your browser doesn't support javascript.
loading
Optimizing antibody affinity and stability by the automated design of the variable light-heavy chain interfaces.
Warszawski, Shira; Borenstein Katz, Aliza; Lipsh, Rosalie; Khmelnitsky, Lev; Ben Nissan, Gili; Javitt, Gabriel; Dym, Orly; Unger, Tamar; Knop, Orli; Albeck, Shira; Diskin, Ron; Fass, Deborah; Sharon, Michal; Fleishman, Sarel J.
Afiliación
  • Warszawski S; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
  • Borenstein Katz A; Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Lipsh R; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
  • Khmelnitsky L; Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Ben Nissan G; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
  • Javitt G; Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Dym O; Israel Structural Proteomics Center, Weizmann Institute of Science, Rehovot, Israel.
  • Unger T; Israel Structural Proteomics Center, Weizmann Institute of Science, Rehovot, Israel.
  • Knop O; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
  • Albeck S; Israel Structural Proteomics Center, Weizmann Institute of Science, Rehovot, Israel.
  • Diskin R; Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Fass D; Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Sharon M; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
  • Fleishman SJ; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
PLoS Comput Biol ; 15(8): e1007207, 2019 08.
Article en En | MEDLINE | ID: mdl-31442220
Antibodies developed for research and clinical applications may exhibit suboptimal stability, expressibility, or affinity. Existing optimization strategies focus on surface mutations, whereas natural affinity maturation also introduces mutations in the antibody core, simultaneously improving stability and affinity. To systematically map the mutational tolerance of an antibody variable fragment (Fv), we performed yeast display and applied deep mutational scanning to an anti-lysozyme antibody and found that many of the affinity-enhancing mutations clustered at the variable light-heavy chain interface, within the antibody core. Rosetta design combined enhancing mutations, yielding a variant with tenfold higher affinity and substantially improved stability. To make this approach broadly accessible, we developed AbLIFT, an automated web server that designs multipoint core mutations to improve contacts between specific Fv light and heavy chains (http://AbLIFT.weizmann.ac.il). We applied AbLIFT to two unrelated antibodies targeting the human antigens VEGF and QSOX1. Strikingly, the designs improved stability, affinity, and expression yields. The results provide proof-of-principle for bypassing laborious cycles of antibody engineering through automated computational affinity and stability design.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Región Variable de Inmunoglobulina / Diseño de Fármacos / Ingeniería de Proteínas / Afinidad de Anticuerpos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: PLoS Comput Biol Asunto de la revista: BIOLOGIA / INFORMATICA MEDICA Año: 2019 Tipo del documento: Article País de afiliación: Israel

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Región Variable de Inmunoglobulina / Diseño de Fármacos / Ingeniería de Proteínas / Afinidad de Anticuerpos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: PLoS Comput Biol Asunto de la revista: BIOLOGIA / INFORMATICA MEDICA Año: 2019 Tipo del documento: Article País de afiliación: Israel